Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Unichem Labs gets tentative USFDA nod for generic version of JnJ Zyrtec-D 12 Hour

      Unichem Labs gets tentative USFDA nod for generic version of JnJ Zyrtec-D 12 Hour

      Farhat Nasim9 May 2019 10:15 AM IST
      Unichem Lab's approved drug is a generic copy of Zyrtec-D 12 Hour which is used for treating allergic rhinitis.New Delhi: Unichem Laboratories Tuesday...
      Lupin gets more time from Government to complete Indore SEZ project

      Lupin gets more time from Government to complete Indore SEZ project

      Farhat Nasim9 May 2019 10:01 AM IST
      The decision to give more time to Lupin for the completion of its project was taken by the Board of Approval (BoA) in its meeting on April 22 here....
      Natco Pharma marketing partner gets USFDA approval for Nitroglycerin Sublingual Tablets

      Natco Pharma marketing partner gets USFDA approval for Nitroglycerin Sublingual Tablets

      Farhat Nasim8 May 2019 10:15 AM IST
      Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood...
      Lupin gets tentative USFDA nod for Fosaprepitant injection

      Lupin gets tentative USFDA nod for Fosaprepitant injection

      Farhat Nasim8 May 2019 10:00 AM IST
      Fosaprepitant for injection is a generic version of Merck Sharp & Dohme Corp's Emend for injection in the same strength.New Delhi: Drug firm Lupin...
      Biocon commercial rights on biosimilar adalimumab extends to global markets

      Biocon commercial rights on biosimilar adalimumab extends to global markets

      Farhat Nasim8 May 2019 9:45 AM IST
      Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing...
      Alembic Pharma JV gets EIR from USFDA for Karakhadi facility

      Alembic Pharma JV gets EIR from USFDA for Karakhadi facility

      Farhat Nasim7 May 2019 10:10 AM IST
      The EIR is for the inspection carried out by USFDA at Alembic Pharma's joint venture, Aleor Dermaceuticals' at Karakhadi, Gujarat, India during the...
      Merck will now be called Procter & Gamble Health

      Merck will now be called Procter & Gamble Health

      Farhat Nasim7 May 2019 10:05 AM IST
      Merck has received approval from the Registrar of Companies, Mumbai, Maharashtra, for change of name from Merck Ltd to Procter & Gamble Health Ltd...
      Dr Reddys launches generic version of AndroGel in US market

      Dr Reddys launches generic version of AndroGel in US market

      Farhat Nasim6 May 2019 10:15 AM IST
      The company's testosterone gel 1.62 per cent, which is a therapeutic equivalent generic version of AndroGel 1.62 per cent of AbbVie Inc, was approved...
      Non-compliance of norms: USFDA recommends action against Strides Pharma Puducherry facility

      Non-compliance of norms: USFDA recommends action against Strides Pharma Puducherry facility

      Farhat Nasim6 May 2019 10:05 AM IST
      Strides Pharma has received a communication from the US Food and Drug Administration (USFDA) on May 4, 2019, classifying the facility as OAI based on...
      Lupin, Zydus Cadila recall products in US; includes BP drug Carvedilol

      Lupin, Zydus Cadila recall products in US; includes BP drug Carvedilol

      Farhat Nasim6 May 2019 10:00 AM IST
      Lupin Somerset is recalling 46,700 bottles of Morphine Sulfate extended-release tablets in various strengths due to "failed impurities/degradation...
      Patent Infringement: Vectura wins case against GSK; awarded $89.7 million in damages

      Patent Infringement: Vectura wins case against GSK; awarded $89.7 million in damages

      Farhat Nasim6 May 2019 9:30 AM IST
      Vectura started legal proceedings against GSK in July 2016 after a patent license agreement between the two companies expired and GSK declined to...
      Eli Lilly to present new data on Emgality, Lasmiditan at AAN annual meeting

      Eli Lilly to present new data on Emgality, Lasmiditan at AAN annual meeting

      Farhat Nasim5 May 2019 10:00 AM IST
      Emgality is also currently under Priority Review by the FDA as an investigational drug for the preventive treatment of episodic cluster headache in...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok